

Pradusinstobart Biosimilar - Research Grade

Product Code: ICH5268

More Information

Species Reactivity: Human

Target: PD-1

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Pradusinstobart Biosimilar - Research Grade

Antibodies against the same target: [Anti-Mouse PD-1 \(29F.1A12\) In Vivo Antibody - Low Endotoxin \(ICH1091\)](#), [Anti-PD-1 \(RMP1-14\) \(ICH1132\)](#), [Anti-Mouse PD-1 \(RMP1-14\) Recombinant Antibody \(ICH1182\)](#), [Mouse Anti-Mouse PD-1 \(29F.1A12\) Recombinant Antibody \(ICH1211\)](#), [Anti-Mouse PD-1 \(RMP1-30\) In Vivo Antibody - Low Endotoxin \(ICH1246\)](#), [Anti-Human PD-1 \(J110\) In Vivo Antibody - Low Endotoxin \(ICH1272\)](#), [Nivolumab Biosimilar - Research Grade \(ICH4009\)](#), [Pembrolizumab Biosimilar - Research Grade \(ICH4029\)](#), [Sintilimab Biosimilar - Research Grade \(ICH5001\)](#), [Toripalimab Biosimilar - Research Grade \(ICH5002\)](#), [Camrelizumab Biosimilar - Research Grade \(ICH5003\)](#), [Tislelizumab Biosimilar - Research Grade \(ICH5004\)](#), [Penpulimab Biosimilar - Research Grade \(ICH5112\)](#), [Cemiplimab Biosimilar - Research Grade \(ICH5161\)](#), [Peresolimab Biosimilar - Research Grade \(ICH5221\)](#), [Acrixolimab Biosimilar - Research Grade \(ICH5224\)](#), [Adebrelimab Biosimilar - Research Grade \(ICH5225\)](#), [Enlonstobart Biosimilar - Research Grade \(ICH5234\)](#), [Ezabenlimab Biosimilar - Research Grade \(ICH5238\)](#), [Finotonlimab Biosimilar - Research Grade \(ICH5241\)](#), [Geptanolimab Biosimilar - Research Grade \(ICH5243\)](#), [Iparomlimab Biosimilar - Research Grade \(ICH5248\)](#), [Lipustobart Biosimilar - Research Grade \(ICH5254\)](#), [Nofazinlimab Biosimilar - Research Grade \(ICH5262\)](#), [Pimivalimab Biosimilar - Research Grade \(ICH5266\)](#), [Pucotenlimab Biosimilar - Research Grade \(ICH5269\)](#), [Sugemalimab Biosimilar - Research Grade \(ICH5278\)](#), [Zimberelimab](#)

[Biosimilar - Research Grade \(ICH5292\)](#), [Retifanlimab Biosimilar - Research Grade \(ICH5296\)](#), [Dostarlimab Biosimilar - Research Grade \(ICH5311\)](#), [Balstilimab Biosimilar - Research Grade \(ICH5369\)](#), [Budigalimab Biosimilar - Research Grade \(ICH5417\)](#), [Cetrelimab Biosimilar - Research Grade \(ICH5434\)](#), [Gilvetmab Biosimilar - Research Grade \(ICH5572\)](#), [Lodapolimab Biosimilar - Research Grade \(ICH5651\)](#), [Pidilizumab Biosimilar - Research Grade \(ICH5773\)](#), [Prolgolimab Biosimilar - Research Grade \(ICH5791\)](#), [Rosnilimab Biosimilar - Research Grade \(ICH5837\)](#), [Rulonilimab Biosimilar - Research Grade \(ICH5840\)](#), [Sasanlimab Biosimilar - Research Grade \(ICH5848\)](#), [Serplulimab Biosimilar - Research Grade \(ICH5855\)](#), [Spartalizumab Biosimilar - Research Grade \(ICH5881\)](#), [Zeluvalimab Biosimilar - Research Grade \(ICH6006\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q15116

Shipping Conditions: Blue ice

background: This is a research-grade biosimilar of Pradusinstobart: an unconjugated, non-therapeutic recombinant human IgG4-kappa antibody analog built around the immune checkpoint receptor PD-1 (PDCD1, UniProt Q15116). It reproduces the antigen-binding specificity of the originator anti-PD-1 molecule and is supplied for research use only. It is not the clinical drug and is not intended for human or veterinary use. The format makes it useful as a defined, well-characterized tool for PD-1/PD-L1 pathway work: as a binding and blockade reagent in receptor-ligand assays, as a positive control or benchmarking standard against other anti-PD-1 clones, as a capture or detection reagent, and as a scaffold for ADCC/ADC-development and engineering studies. The IgG4 backbone (typically stabilized) recapitulates the reduced effector-function profile expected of checkpoint-blocking antibodies. Material is offered at research grade with low endotoxin (1 EU/mg standard; 0.5 EU/mg ultra-low options), enabling sensitive cell-based and in-vitro immunology assays, and is available in bulk milligram-to-gram quantities to support preclinical and assay-development pipelines requiring lot-consistent, animal-origin-free recombinant protein. PD-1 (Programmed cell death protein 1; gene PDCD1; UniProt Q15116; also CD279) is a type I transmembrane immunoinhibitory receptor of the CD28/B7 immunoglobulin superfamily. It is expressed on activated T cells, B cells, NK cells, and other immune subsets, and is upregulated with chronic antigen exposure. Its cytoplasmic tail carries an ITIM and an ITSM; engagement by its ligands PD-L1 (CD274) and PD-L2 (PDCD1LG2) recruits the phosphatase

SHP-2, which dephosphorylates TCR and CD28 signaling components, dampening T-cell activation, proliferation, and cytokine output. This axis maintains peripheral tolerance and limits immunopathology, but tumors and chronically infected tissues exploit it to drive T-cell exhaustion. Blocking PD-1 or its ligands restores effector function, the mechanistic basis of checkpoint-inhibitor immunotherapy.

Other names: Protein PD-1, hPD-1, Programmed cell death protein 1, PDCD1

Specificity: Detects human PD-1

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks